Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
Public ClinicalTrials.gov record NCT04626479. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (U03): Substudy 03A in First Line Metastatic Participants
Study identification
- NCT ID
- NCT04626479
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 400 participants
Conditions and interventions
Conditions
Interventions
- Belzutifan Drug
- Favezelimab/Pembrolizumab Biological
- Lenvatinib Drug
- Pembrolizumab Biological
- Pembrolizumab/Quavonlimab Biological
- Vibostolimab/Pembrolizumab Drug
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years to 120 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 15, 2020
- Primary completion
- Jul 16, 2026
- Completion
- Jul 16, 2026
- Last update posted
- May 5, 2026
2020 – 2026
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California at San Francisco ( Site 1008) | San Francisco | California | 94158 | — |
| Yale-New Haven Hospital-Yale Cancer Center ( Site 1011) | New Haven | Connecticut | 06510 | — |
| University of Chicago ( Site 1013) | Chicago | Illinois | 60637 | — |
| University of Iowa ( Site 1012) | Iowa City | Iowa | 52242 | — |
| Henry Ford Health System ( Site 1014) | Detroit | Michigan | 48202 | — |
| Laura and Isaac Perlmutter Cancer Center ( Site 1016) | New York | New York | 10016 | — |
| Memorial Sloan Kettering Cancer Center ( Site 1002) | New York | New York | 10065 | — |
| Duke Cancer Institute ( Site 1015) | Durham | North Carolina | 27710 | — |
| UPMC Cancer Center/Hillman Cancer Center ( Site 1017) | Pittsburgh | Pennsylvania | 15232 | — |
| UTSW Medical Center ( Site 1003) | Dallas | Texas | 75390 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 45 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04626479, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 5, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04626479 live on ClinicalTrials.gov.